lu-99

Gimeracil (Gimestat) is a competitive, reversible inhibitor of dihydropyrimidine dehydrogenase.

Eras-4001 is a small-molecule pan-KRAS inhibitor capable of targeting both wild-type KRAS and various mutant forms simultaneously. Eras-4001 inhibits signaling between KRAS and effector proteins such as RAF, thereby blocking the activity of the RAS/MAPK pathway. In preliminary studies, this compound has demonstrated high affinity for KRAS (nano-molar IC₅₀) and induced tumor regression in multiple KRAS-mutant tumor models, indicating potential value for antitumor therapy.

Alisertib (MLN 8237) is a specific Aurora A inhibitor (IC50: 1.2 nM). The selectivity of Alisertib(MLN 8237) is >200-fold higher for Aurora A than Aurora B.

BLU9931 is the first selective small molecule inhibitor of FGFR4.